Last reviewed · How we verify
PA9159 Inhalation aerosol, 120 μg one day treatment
PA9159 Inhalation aerosol, 120 μg one day treatment is a Small molecule drug developed by Anhui Palo Alto Pharmaceuticals, Inc.. It is currently in Phase 1 development.
At a glance
| Generic name | PA9159 Inhalation aerosol, 120 μg one day treatment |
|---|---|
| Sponsor | Anhui Palo Alto Pharmaceuticals, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study on the Safety and Efficacy of PA9159 Inhalation Aerosol for the Treatment of Adult Bronchial Asthma (PHASE2)
- Safety, Tolerability, and Pharmacokinetics of PA9159 Inhalation Aerosol in Healthy Adult Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PA9159 Inhalation aerosol, 120 μg one day treatment CI brief — competitive landscape report
- PA9159 Inhalation aerosol, 120 μg one day treatment updates RSS · CI watch RSS
- Anhui Palo Alto Pharmaceuticals, Inc. portfolio CI
Frequently asked questions about PA9159 Inhalation aerosol, 120 μg one day treatment
What is PA9159 Inhalation aerosol, 120 μg one day treatment?
PA9159 Inhalation aerosol, 120 μg one day treatment is a Small molecule drug developed by Anhui Palo Alto Pharmaceuticals, Inc..
Who makes PA9159 Inhalation aerosol, 120 μg one day treatment?
PA9159 Inhalation aerosol, 120 μg one day treatment is developed by Anhui Palo Alto Pharmaceuticals, Inc. (see full Anhui Palo Alto Pharmaceuticals, Inc. pipeline at /company/anhui-palo-alto-pharmaceuticals-inc).
What development phase is PA9159 Inhalation aerosol, 120 μg one day treatment in?
PA9159 Inhalation aerosol, 120 μg one day treatment is in Phase 1.